Related Experiment Video
Updated: Mar 27, 2026

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
Published on: September 21, 2021
Protective effects of adenosine A2B receptor antagonism in a cuprizone-induced demyelination model
Cherchi Federica1, Venturini Martina2, Frulloni Lucia2
1Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy; Department of Neuroscience and Human Genetics, Meyer Children's Hospital IRCCS, Florence, Italy.
Abstract:
Demyelinating diseases are characterized by the progressive loss of myelin in the central nervous system (CNS). Myelin protection can be achieved by fostering the differentiation of oligodendrocyte progenitor cells to mature oligodendrocytes, the only myelinating cells in the brain. Oligodendrocytes maturation is sustained, among others, by the neuromodulator adenosine through the activation of its specific receptors: A1, A2A, A2B, A3, all expressed in the brain on neurons and glial cells. The role of A2B receptors (A2BRs) in a cuprizone-induced demyelination model in male C57BL/6 mice was investigated by administering the selective A2BR agonist BAY60-6583 or antagonist PSB 603 during the last 2 weeks of a 5-week cuprizone-based diet. We performed body weight evaluation, behavioural tests and immunofluorescence analysis. Cuprizone-fed mice showed a significant decrease in body weight gain, a motor impairment and a reduced spontaneous mobility. These effects were associated with a decrease in myelin levels, a reactive astrogliosis and microgliosis in corpus callosum medialis, striatum and motor cortex. PSB 603, was able to prevent cuprizone effects on glia, whereas both compounds promoted a significant recovery in motor deficits. The antagonism of A2BRs might represent an attractive strategy to alleviate myelin damage and glial activation in the CNS under conditions of demyelination.
More Related Videos
04:43Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research
Published on: June 16, 2023
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Related Concept Videos
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Desensitization and Tachyphylaxis
Drugs Affecting Neurotransmitter Release or Uptake